Research
Hormonal
Bariatric surgery induces early, pronounced improvements in hepatic and peripheral insulin sensitivity and glycemic control that occur independently of significant weight loss, primarily through anatomical remodeling of the gastrointestinal tract.
If you have severe obesity and type 2 diabetes, bariatric surgery can resolve your diabetes through hormonal changes in your gut, not just by making you smaller. This happens quickly, often before you lose much weight. Consult a multidisciplinary unit to see if you are a candidate.
GoodSupportsHIGH confidence
the metabolic improvements after BS take place in the days or weeks after surgery even before significant weight loss occurs... mechanisms other than weight loss that cannot be explained solely by caloric restriction are likely triggered after BS and could account for the beneficial metabolic changes observed.
Why this rating
The paper cites multiple RCTs (SMBOSS, STAMPEDE, SLEEVEPASS) and meta-analyses, though it notes heterogeneity in study designs.
Source
Metabolic and Endocrine Consequences of Bariatric Surgery
Isabel Cornejo‐Pareja et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00626
narrative_reviewCited 112×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery leads to long-term nutrient deficiencies (anemia, neuropathies, osteoporosis) due to malabsorption and reduced gastric acid, requiring lifelong monitoring and supplementation.Strong
- Bariatric surgery resolves Polycystic Ovary Syndrome (PCOS) symptoms, including menstrual irregularities and hirsutism, and improves fertility in obese women, largely through weight loss and hormonal normalization.Good
- Bariatric surgery reverses obesity-associated secondary hypogonadism (MOSH) in men, leading to increased total and free testosterone levels and improved sexual function.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →